| Literature DB >> 35430877 |
Shuai Xu1, Ming Wei2, Gang Li3, Zhenpeng Li1, Yanlin Che4, Lichao Han1, Wei Jia3, Fang Li5, Dan Li1, Zhenjun Li1.
Abstract
Nocardia cyriacigeorgica is a common etiological agent of nocardiosis that has increasingly been implicated in serious pulmonary infections, especially in immunocompromised individuals. However, the evolution, diversity, and pathogenesis of N. cyriacigeorgica have remained unclear. Here, we performed a comparative genomic analysis using 91 N. cyriacigeorgica strains, 45 of which were newly sequenced in this study. Phylogenetic and average nucleotide identity (ANI) analyses revealed that N. cyriacigeorgica contained five species-level clades (8.6 to 14.6% interclade genetic divergence), namely, the N. cyriacigeorgica complex (NCC). Further pan-genome analysis revealed extensive differences among the five clades in nine functional categories, such as energy production, lipid metabolism, secondary metabolites, and signal transduction mechanisms. All 2,935 single-copy core genes undergoing purifying selection were highly conserved across NCC. However, clades D and E exhibited reduced selective constraints, compared to clades A to C. Horizontal gene transfer (HGT) and mobile genetic elements contributed to genomic plasticity, and clades A and B had experienced a higher level of HGT events than other clades. A total of 129 virulence factors were ubiquitous across NCC, such as the mce operon, hemolysin, and type VII secretion system (T7SS). However, different distributions of three toxin-coding genes and two new types of mce operons were detected, which might contribute to pathogenicity differences among the members of the NCC. Overall, our study provides comprehensive insights into the evolution, genetic diversity, and pathogenicity of NCC, facilitating the prevention of infections. IMPORTANCE Nocardia species are opportunistic bacterial pathogens that can affect all organ systems, primarily the skin, lungs, and brain. N. cyriacigeorgica is the most prevalent species within the genus, exhibits clinical significance, and can cause severe infections when disseminated throughout the body. However, the evolution, diversity, and pathogenicity of N. cyriacigeorgica remain unclear. Here, we have conducted a comparative genomic analysis of 91 N. cyriacigeorgica strains and revealed that N. cyriacigeorgica is not a single species but is composed of five closely related species. In addition, we discovered that these five species differ in many ways, involving selection pressure, horizontal gene transfer, functional capacity, pathogenicity, and antibiotic resistance. Overall, our work provides important clues in dissecting the evolution, genetic diversity, and pathogenicity of NCC, thereby advancing prevention measures against these infections.Entities:
Keywords: Nocardia cyriacigeorgica complex; comparative genomics; evolution; genetic diversity; pan-genome; pathogenicity; taxonomy
Year: 2022 PMID: 35430877 PMCID: PMC9239197 DOI: 10.1128/msystems.01406-21
Source DB: PubMed Journal: mSystems ISSN: 2379-5077 Impact factor: 7.324
FIG 1Genome size, number of CDSs, and GC content of genomes analyzed in this study. (A) Genome size, (B) number of CDSs, and (C) GC content. The genomes are colored based on phylogenetic clades as defined in Fig. 2B.
FIG 2Phylogenetic trees of 91 genome assemblies of N. cyriacigeorgica complex. (A) The dapb1-based phylogenetic tree. (B) The phylogenomic tree constructed based on the concatenation of the nucleotide sequences of 2,935 single-copy core genes. The isolation source, geographical origin, and date of sampling are shown. Each tree was built using the maximum likelihood method, with 1,000 bootstrap replicates. The genome sequence of N. carnea DSM 43397T was used as an outgroup, and its branch length was shortened for better visualization. Bootstrap values are indicated on the nodes, and five main phylogenetic clades are highlighted in different colors.
FIG 3Heat map of pairwise ANI values for 91 genome assemblies of N. cyriacigeorgica complex.
FIG 4Distribution of the number of orthogroups in the N. cyriacigeorgica complex. Horizontal bars indicate the number of core and accessory orthogroups in the five clades. Vertical bars represent the number of clade-specific orthogroups or shared orthogroups between the five clades. Clade-specific orthogroups are indicated in blue, and their distributions of functional categories based on eggNOG annotation are shown in the inset. The orthogroups unique to clades A and D are indicated in pink, whereas the orthogroups unique to clades A to D are in purple.
FIG 5PCoA plots of predicted functional classification in each clade based on eggNOG annotation. Each point represents a genome that is colored based on its clade.
FIG 6Selective pressure on 2,935 single-copy core genes of five clades in the N. cyriacigeorgica complex.
FIG 7Distribution of horizontally transferred genes and MGEs in the N. cyriacigeorgica complex. (A) The top 10 potential donor bacterial genera provided donor genes for HGT. (B) The number of HGT-acquired genes in each genome. (C) The distribution of MGEs.
FIG 8Virulence genes in the genomes of N. cyriacigeorgica complex. (A) Differences among virulence genes per clade by PCoA plot. (B) Distribution of the toxin-coding genes and mce operons. Each dot indicates the presence of the gene or operon. (C) Comparison of different types of mce operons. Regions of homology are indicated by blue shading.
FIG 9Distribution pattern of ARGs in the genomes of N. cyriacigeorgica complex. Each dot indicates the presence of a gene. Different colors indicate different types of ARGs.
Antimicrobial resistance among clades and correlations with antibiotic resistance gene presence
| Drug type | Drug | Concn range (μg/mL) | No. (%) of resistant isolates | Clades | Predicted ARGs | MIC (μg/mL) | ||
|---|---|---|---|---|---|---|---|---|
| Range | MIC50 | MIC90 | ||||||
| β-Lactam antibiotics | AXO | 4 to 64 | 6 (10) | A (5), B (0), D (1) | <4 to >64 | <4 | >64 | |
| FOX | 4 to 128 | 57 (95) | A (38), B (6), D (13) | 64 to >128 | >128 | >128 | ||
| AUG2 | 1 to 64 | 54 (90) | A (37), B (6), D (11) | 16/8 to >64/32 | 64/32 | >64/32 | ||
| FEP | 1 to 32 | 30 (50) | A (22), B (1), D (7) | 4 to >32 | 32 | >32 | ||
| IMI | 2 to 64 | 52 (86) | A (35), B (6), D (11) | <2 to >64 | 32 | >64 | ||
| Aminoglycoside antibiotics | KAN | 0.5 to 256 | 54 (90) | A (36), B (5), D (13) | 16 to 256 | 64 | 256 | |
| TOB | 1 to 16 | 0 (0) | 0 | <1 | <1 | <1 | ||
| AMI | 1 to 64 | 0 (0) | 0 | <1 | <1 | <1 | ||
| Streptogramin antibiotic | STR | 0.5 to 256 | 38 (63) | A (34), B (4), D (0) | 1 to >256 | >256 | >256 | |
| Fluoroquinolone antibiotics | MXF | 0.25 to 8 | 45 (75) | A (31), B (2), D (12) | 2 to >8 | 4 | 8 | |
| CIP | 0.12 to 4 | 58 (96) | A (37), B (6), D (15) | 2 to >4 | >4 | >4 | ||
| LVX | 0.5 to 256 | 58 (96) | A (37), B (6), D (15) | 2 to 32 | 8 | 32 | ||
| Glycopeptide antibiotic | VAN | 0.5 to 256 | 55 (81) | A (34), B (5), D (10) | 0.5 to >256 | 256 | >256 | |
| Macrolide antibiotic | CLA | 0.06 to 16 | 52 (86) | A (35), B (6), D (11) | 2 to >16 | >16 | >16 | |
| Tetracycline antibiotics | DOX | 0.12 to 16 | 0 (0) | 0 | 0.25 to 4 | 2 | 4 | |
| MIN | 1 to 8 | 0 (0) | 0 | <1 to 4 | 2 | 4 | ||
| TGC | 0.015 to 4 | 0 (0) | 0 | 0.25 to 2 | 1 | 1 | ||
| Sulfonamide antibiotic | SXT | 0.25 to 152 | 0 (0) | 0 | <0.25/4.75 to 0.5/9.5 | <0.25/4.75 | 0.5/9.5 | |
| Oxazolidinone antibiotic | LZD | 1 to 32 | 0 (0) | 0 | <1 to 2 | <1 | 2 | |
AXO, ceftriaxone; FOX, cefoxitin; AUG2, amoxicillin-clavulanic acid; FEP, cefepime; IMI, imipenem; KAN, kanamycin; TOB, tobramycin; AMI, amikacin; STR, streptomycin; MXF, moxifloxacin; CIP, ciprofloxacin; LVX, levofloxacin; VAN, vancomycin; CLA, clarithromycin; DOX, doxycycline; MIN, minocycline; TGC, tigecycline; SXT, trimethoprim-sulfamethoxazole; LZD, linezolid.
Values in parentheses show the number of isolates resistant to a drug.
The MIC is defined as the lowest concentration of a drug that completely inhibits the visible growth of the tested isolates, the MIC50 is defined as the MIC value of a drug capable of inhibiting the growth of 50% of tested isolates, and the MIC90 is defined as the MIC value of a drug capable of inhibiting the growth of 90% of tested isolates.